April 28, 2011

Strong performance of growth platforms in Q1 2011

 

Strong performance of growth platforms in Q1 2011

Commenting on the Group’s performance in Q1 2011, sanofi-aventis Chief Executive Officer, Christopher A. Viehbacher said, “This quarter, the year-on-year comparison must take into account the absence of non-recurring A/H1N1 sales. I’m particularly satisfied with the performance of our growth platforms which were up 15.5% (excluding A/H1N1) and now represent almost 60% of Group sales; these businesses have compensated for the impact of generic competition on net sales and represent the future of our company. As of this quarter, we now fully consolidate Merial, our animal health division which delivered a strong performance. We have also closed the Genzyme transaction and the integration phase has started favorably.”